

NOTICE OF ALLOWANCE

This action is in response to the amendment and declaration filed January 22, 2010. Claims 1-33 have been cancelled. Claims 34-41 are new claims. All of the amendments and declaration have been thoroughly reviewed and entered. The previous rejections in the Office action mailed on 8/4/09 are withdrawn in view of the amendments.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Luke Kilyk on January 27, 2010.

The claims have been amended as follows:

34. (Currently Amended) A method of identifying a compound having an effect of enhancing expression and/or function of sFRP (secreted frizzled-related protein), comprising:

a) providing using a mouse that is deficient in both of Dlg (discs large) alleles;

- b) administering a test compound to the mouse; and
- c) measuring expression and/or function of sFRP.

35. (Currently Amended) A method of identifying a compound having an effect of enhancing expression and/or function of sFRP (secreted frizzled-related protein), comprising:

- a) providing using a cell originating in a mouse that is deficient in both of Dlg alleles;
- b) contacting a test compound with the cell; and
- c) measuring expression and/or function of sFRP.

38. (Currently Amended) A method of identifying a compound that inhibits tumor formation, comprising:

- a) providing using a mouse that is deficient in both of Dlg (discs large) alleles;
- b) administering a test compound to the mouse; and
- c) measuring expression and/or function of sFRP, and
- d) testing or utilizing said test compound for inhibition of tumor formation if said compound has an effect of enhancing expression and/or function of sFRP.

39. (Currently Amended) A method of identifying a compound that inhibits tumor formation, comprising:

a) providing using a cell originating in a mouse that is deficient in both of Dlg alleles;

b) contacting a test compound with the cell; and

c) measuring expression and/or function of sFRP, and

d) testing or utilizing said test compound for inhibition of tumor formation if
said compound has an effect of enhancing expression and/or function of sFRP.

Conclusion

Claims 34-41 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Q. Janice Li** whose telephone number is 571-272-0730. The examiner can normally be reached on 9:30 am - 7 p.m., Monday through Friday, except every other Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph Woitach** can be reached on 571-272-0739. The fax numbers for the organization where this application or proceeding is assigned are **571-273-8300**.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

*/Q. JANICE LI, M.D./
Primary Examiner, Art Unit 1633*